Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line FOLFIRI plus bevacizumab stratified by LDH in advanced colorectal cancer
2012-005048-46Phase 2Active
- Sponsor
- Fondazione GISCAD
- Start
- May 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab, irinotecan, fluorouracil and levoleucovorin in colorectal cancer (CRC) (2 arms), sponsored by Fondazione GISCAD. Primary endpoint: Objective response rate. Started May 2013; status: active.
02
Drugs
bevacizumabirinotecanfluorouracillevoleucovorin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2012-005048-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005048-46.